Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 45 - Medicinal preparations containing active ingredients not provided for in groups
Patents for A61K 45 - Medicinal preparations containing active ingredients not provided for in groups (115,020)
06/2000
06/29/2000WO2000002543A3 Antihypersensitive combination of valsartan and calcium channel blocker
06/29/2000WO2000000610A3 Human signal peptide-containing proteins
06/29/2000WO1999066909A3 Method and compositions for the treatment or amelioration of female sexual dysfunction
06/29/2000WO1999064034A9 β2-ADRENERGIC RECEPTOR AGONISTS
06/29/2000WO1999063974A3 Selective estrogen receptor modulator in combination with denydroepiandrosterone (dhea) or analogues
06/29/2000WO1999055854A3 Insulin-like growth factor ii antisense oligonucleotide sequences and methods of using same to modulate cell growth
06/29/2000DE19909771A1 Substanz zur Gewinnung hochwirksamer Tumorarzneien sowie Verfahren Substance for the production of highly effective tumor drugs and methods
06/29/2000DE19860132A1 Use of allergens or allergenic vaccines in the treatment of allergies
06/29/2000DE19859727A1 Die Verwendung von Hemmern des Natrium-Wasserstoff-Austauschers zur Herstellung eines Medikaments zur Verhinderung von altersbedingten Organ-Dysfunktionen, altersbedingten Erkrankungen zur Lebensverlängerung The use of inhibitors of the sodium-hydrogen exchanger for preparing a medicament for preventing age-related organ dysfunctions, age-related diseases for prolonging life
06/29/2000CA2450402A1 Methods and compositions for inhibiting cancer cell growth comprising pro224
06/29/2000CA2358492A1 Combination therapy for the treatment of sepsis
06/29/2000CA2358086A1 Protein-protein interactions in neurodegenerative disorders
06/29/2000CA2357413A1 Sensitizing agents for the treatment of skin lesions
06/29/2000CA2356887A1 Assays for ligands for nuclear receptors
06/29/2000CA2356624A1 Endocrine therapy for breast cancer: combined treatment with tamoxifen plus alkyl pcdfs
06/29/2000CA2356460A1 Compounds, methods of screening and methods of treatment for central and peripheral nervous system disorders
06/29/2000CA2356426A1 Method of using a cyclooxygenase-2 inhibitor and a matrix metalloproteinase inhibitor as a combination therapy in the treatment of neoplasia
06/29/2000CA2356366A1 Oil-in-water emulsion comprising a micronised biologically active agent and an appropriate emulsifier system
06/29/2000CA2356246A1 Use of 5ht3-receptor antagonists for the treatment of chronic fatigue syndrome
06/29/2000CA2356174A1 Kidney disease detection and treatment
06/29/2000CA2355879A1 Pharmaceutical compositions comprising immortalised endothelial cells
06/29/2000CA2355848A1 Dihydropyrimidines and uses thereof
06/29/2000CA2355830A1 Crystalline form of activated trap and use thereof for structure-based drug design
06/29/2000CA2355630A1 Compounds useful in the treatment of inflammatory diseases
06/29/2000CA2355368A1 Cgmp pde 5 inhibitors for inhalation in the treatment of sexual dysfunction
06/29/2000CA2355074A1 Lymphocytic membrane proteins
06/29/2000CA2354074A1 Method of identifying a psychotropic agent using differential gene expression
06/29/2000CA2353848A1 Large molecule drug delivery system using aerosolized membrane-mimetic amphiphiles
06/29/2000CA2353775A1 Compositions and methods for the treatment of tumor
06/29/2000CA2353635A1 Anilide derivative, production and use thereof
06/29/2000CA2352326A1 Combination chemotherapy
06/29/2000CA2351674A1 Use of a 5ht2a and 5ht2a/c receptor antagonist for preparing medicines for treating snoring and high resistance syndrome of upper anatomical airways
06/29/2000CA2346960A1 Diagnostic and therapeutics for sepsis
06/29/2000CA2333626A1 Method for prevention and treatment of cancer and other cell proliferative diseases with ultrasonics
06/29/2000CA2293081A1 Restenosis drug therapy
06/28/2000EP1013286A2 Vitamin preparation, process for production and use thereof
06/28/2000EP1013285A2 Urokinase-type plasminogen activator receptor
06/28/2000EP1013281A1 hCG therapy for the treatment of breast cancer
06/28/2000EP1013276A1 Aminoazacycloalkanes as CCR5 modulators
06/28/2000EP1012329A1 Diagnosis and treatment of myocardial failure
06/28/2000EP1012320A2 Use of multivalent chimeric peptide-loaded, mhc/ig molecules to detect, activate or suppress antigen-specific t cell-dependent immune responses
06/28/2000EP1012308A1 Compounds, compositions and methods for the endocytic presentation of immunosuppressive factors
06/28/2000EP1012302A1 Human nucleotide pyrophosphohydrolase
06/28/2000EP1012288A1 Novel human cystatin-like protein
06/28/2000EP1012282A1 Cysteine rich receptors-train
06/28/2000EP1012281A2 Human leukocyte calcium activated potassium channel polypeptide
06/28/2000EP1012272A1 Human apoptosis-associated protein; encoding dna is similar to p53 response mouse gene ei124
06/28/2000EP1012271A1 Methods for the diagnosis, prognosis and treatment of glaucoma and related disorders
06/28/2000EP1012270A2 Kay - a novel immune system protein
06/28/2000EP1012262A1 Human frezzled-like protein
06/28/2000EP1012242A1 Human sigma receptor
06/28/2000EP1012188A1 Composition for treating diabetes mellitus and obesity
06/28/2000EP1012187A2 Chemokine peptides, variants, derivatives and analogs. their use in methods to inhibit or augment an inflammatory response
06/28/2000EP1012180A2 Hepatitis c inhibitor peptide analogues
06/28/2000EP1012179A2 Cysteine rich receptors: trail
06/28/2000EP1012177A1 Estrogen receptor
06/28/2000EP1012162A4 Soluble proteins
06/28/2000EP1012162A1 Soluble proteins
06/28/2000EP1012158A1 Mycobacterium fol a gene that encodes for the enzyme dihydrofolate reductase
06/28/2000EP1011726A2 Fused imidazole derivatives for improving oral bioavailability of pharmaceutical agents
06/28/2000EP1011724A1 Regulation of osteoclast formation by inhibition of osteoblastic stem cell factor
06/28/2000EP1011719A1 Synthetic antigens for cd1-restricted immune responses
06/28/2000EP1011718A1 Anti-viral treatment with pertussis toxin b oligomer
06/28/2000EP1011710A1 Methods and compositions for optimization of oxygen transport by cell-free systems
06/28/2000EP1011709A1 Inhibition of apoptotis using prosaposin receptor agonists
06/28/2000EP1011705A2 Conjugates targeted to the interleukin-2 receptor
06/28/2000EP1011698A1 Chemical supplementation of bone
06/28/2000EP1011695A1 Use of neurotoxin therapy for treatment of urologic and related disorders
06/28/2000EP1011690A1 Cross-linked polysaccharide drug carrier
06/28/2000EP1011688A1 Use of uridine 5'-diphosphate and analogs thereof for the treatment of lung diseases
06/28/2000EP1011686A1 Modulation of human mast cell activation
06/28/2000EP1011685A1 Method of treating cancer using alkylglycerols in conjunction with chemotherapy
06/28/2000EP1011682A2 Hormonal contraceptive
06/28/2000EP1011678A1 Nicotine antagonists for nicotine-responsive neuropsychiatric disorders
06/28/2000EP1011673A1 Novel niddm regimen
06/28/2000EP1011671A1 Substance dependence treatment using opiate antagonists and serotonin compounds
06/28/2000EP1011670A1 Method for treatment of non-rheumatoid athritis
06/28/2000EP1011667A1 Antagonists of gonadotropin releasing hormone
06/28/2000EP1011662A1 Improved compositions and methods for the control of smoking
06/28/2000EP1011658A1 Analgesic compositions comprising anti-epileptic compounds and methods of using same
06/28/2000EP1011655A1 Inhibitors of leaderless protein export
06/28/2000EP1011654A1 A method of modulating cellular activity
06/28/2000EP1011651A1 Method of treating diabetes and related disease states
06/28/2000EP1011648A2 Combination of tyrosine kinase inhibitor and chemical castration to treat prostate cancer
06/28/2000EP1011638A1 Small particle liposome aerosols for delivery of anti-cancer drugs
06/28/2000EP1011637A1 Modulation of drug loading in multivesicular liposomes
06/28/2000EP1011636A1 New foam-forming pharmaceutical composition
06/28/2000EP1011634A1 Preparation of pharmaceutical compositions
06/28/2000EP1011631A1 Antacid composition
06/28/2000EP1011608A2 Composition and method for prevention and treatment of cardiopulmonary and renal failure or damage associated with ischemia, endotoxin release, ards or brought about by administration of certain drugs
06/28/2000EP1011567A1 Drug delivery devices and methods for treatment of viral and microbial infections and wasting syndromes
06/28/2000CN1258198A Utilisations of oil bodies
06/28/2000CN1258191A Antimicrobial prevention and treatment of human immunedeficiency virus and other infectious diseases
06/28/2000CN1053838C Synergism of TNF and IL-4
06/27/2000US6080877 Taxanes
06/27/2000US6080778 Methods for decreasing beta amyloid protein
06/27/2000US6080773 Benzylamine derivatives which are useful in treating psychiatric disorders
06/27/2000US6080765 Pharmaceutical composition
06/27/2000US6080744 Topical antifungal treatment
06/27/2000US6080741 Arglabin compounds and therapeutic uses thereof
1 ... 969 970 971 972 973 974 975 976 977 978 979 980 981 982 983 984 985 986 987 988 989 ... 1151